Literature DB >> 20064703

The investigator and the IRB: a survey of depression and schizophrenia researchers.

Bernard A Fischer1, Praveen George.   

Abstract

Despite the integral part Institutional Review Boards (IRBs) play in U.S. research, research on IRBs is lacking. This is especially true in the area of mental health investigator-IRB interactions. It was hypothesized that schizophrenia researchers would have a different experience with IRBs as compared to depression researchers. This would include longer turn-around time and fewer protocols approved on first submission. It was also thought that schizophrenia researchers would be more hesitant to submit ethically complex protocols for IRB review. 396 NIH-funded schizophrenia and depression investigators were invited to participate in a survey study on IRBs. 108 usable responses were returned, 45 of which were from schizophrenia researchers. Schizophrenia researchers were significantly less likely to submit ethically complex protocols for IRB review than depression researchers even when controlling for academic rank, years of research experience, type of research done, and the need to submit to multiple IRBs. However, there was no significant difference between researcher groups in IRB review turn-around time or initial approval rates. As a group, respondents found IRB submission paperwork burdensome but necessary and were almost evenly split as to whether IRB comments were helpful (54.8%) or not (45.2%). Time to initial review was 3 weeks or longer for most respondents. 94.4% agreed IRBs should enforce subject privacy and 68.2% agreed they should monitor conflict of interest, but only 37.% agreed IRBs should review study design. Conclusions are that 1. the population studied may have profound impacts on the type of protocols submitted to IRBs even within the field of mental health, 2. IRBs may not draw as large a distinction between depression and schizophrenia protocols as researchers believe, and 3. facilitating IRB review by eliminating evaluation of design may be possible if the protocol has already been vetted by a credible funding agency (such as the U.S. National Institutes of Health). (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20064703      PMCID: PMC2895950          DOI: 10.1016/j.schres.2009.12.019

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  29 in total

1.  Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary?

Authors:  C Weijer
Journal:  Schizophr Res       Date:  1999-02-15       Impact factor: 4.939

2.  Ethical concerns in schizophrenia research: looking back and moving forward.

Authors:  Scott T Wilson; Barbara Stanley
Journal:  Schizophr Bull       Date:  2005-11-10       Impact factor: 9.306

3.  A summary of important documents in the field of research ethics.

Authors:  Bernard A Fischer
Journal:  Schizophr Bull       Date:  2005-09-28       Impact factor: 9.306

4.  Structure and practice of institutional review boards in the United States.

Authors:  J S Jones; L J White; L C Pool; J M Dougherty
Journal:  Acad Emerg Med       Date:  1996-08       Impact factor: 3.451

5.  Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.

Authors:  Scott Stroup; Paul Appelbaum; Marvin Swartz; Mukesh Patel; Sonia Davis; Dilip Jeste; Scott Kim; Richard Keefe; Theo Manschreck; Joseph McEvoy; Jeffrey Lieberman
Journal:  Schizophr Res       Date:  2005-09-22       Impact factor: 4.939

6.  Using a brief intervention to improve decisional capacity in schizophrenia research.

Authors:  David J Moser; Rebecca L Reese; Clare T Hey; Susan K Schultz; Stephan Arndt; Leigh J Beglinger; Kevin M Duff; Nancy C Andreasen
Journal:  Schizophr Bull       Date:  2005-09-21       Impact factor: 9.306

7.  When does decisional impairment become decisional incompetence? Ethical and methodological issues in capacity research in schizophrenia.

Authors:  Scott Y H Kim
Journal:  Schizophr Bull       Date:  2005-09-21       Impact factor: 9.306

8.  Protection of persons with mental disorders from research risk: a response to the report of the National Bioethics Advisory Commission.

Authors:  J M Oldham; S Haimowitz; S J Delano
Journal:  Arch Gen Psychiatry       Date:  1999-08

Review 9.  Magnitude of impairment in decisional capacity in people with schizophrenia compared to normal subjects: an overview.

Authors:  Dilip V Jeste; Colin A Depp; Barton W Palmer
Journal:  Schizophr Bull       Date:  2005-09-28       Impact factor: 9.306

10.  Willingness and competence of depressed and schizophrenic inpatients to consent to research.

Authors:  Bruce J Cohen; Elizabeth L McGarvey; Relana C Pinkerton; Ludmila Kryzhanivska
Journal:  J Am Acad Psychiatry Law       Date:  2004
View more
  1 in total

1.  Research approvals iceberg: how a 'low-key' study in England needed 89 professionals to approve it and how we can do better.

Authors:  Mila Petrova; Stephen Barclay
Journal:  BMC Med Ethics       Date:  2019-01-25       Impact factor: 2.652

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.